Besides, the anti-tumor immunity conferred by CD8+ T cell contributed to tumor regression and improved prognosis in NPC patients (54, 55), which in line with our finding that low KIF18B expression group exhibited better prognosis. The gene discussed is CD8A; the disease is neoplasm.